Table 1.
Clinical characteristics of study participants.
| Male | Female | |||||
|---|---|---|---|---|---|---|
| 20–44 Years | 44–64 Years | ≥65 Years | 20–44 Years | 44–64 Years | ≥65 Years | |
| Age (year) | 34.3 ± 5.7 * | 54.3 ± 5.9 ** | 70.4 ± 5.6 *** | 35.3 ± 5.9 † | 55.8 ± 5.6 †† | 70.9 ± 5.3 ††† |
| Height (cm) | 172.7 ± 5.4 * | 169.2 ± 5.8 ** | 163.1 ± 8.4 *** | 159.4 ± 5.4 † | 156.1 ± 5.2 †† | 151.0 ± 5.1 ††† |
| Weight (kg) | 70.1 ± 11.8 | 68.0 ± 8.8 ** | 62.0 ± 8.4 *** | 54.5 ± 10.1 | 53.8 ± 7.8 | 51.9 ± 7.9 ††† |
| BMI | 23.4 ± 3.6 | 23.7 ± 2.7 | 23.3 ± 2.9 | 21.4 ± 4.0 | 22.0 ± 3.1 | 22.7 ± 3.1 ††† |
| AA (μg/dL) | 234.1 ± 56.4 | 236.2 ± 59.6 ** | 202.4 ± 47.1 *** | 209.1 ± 40.5 † | 226.7 ± 47.7 †† | 206.4 ± 46.1 |
| DGLA (μg/dL) | 50.5 ± 15.7 | 53.4 ± 16.8 ** | 39.4 ± 13.3 *** | 40.4 ± 14.6 † | 45.6 ± 13.8 †† | 41.3 ± 12.9 |
| AA/DGLA | 4.88 ± 1.27 | 4.66 ± 1.28 ** | 5.50 ± 1.53 *** | 5.60 ± 1.62 | 5.29 ± 1.51 | 5.31 ± 1.46 |
| EPA (μg/dL) | 50.0 ± 26.5 * | 82.1 ± 45.9 ** | 125.9 ± 62.5 *** | 43.1 ± 22.8 † | 82.6 ± 43.6 †† | 117.6 ± 61.6 ††† |
| DHA (μg/dL) | 127.4 ± 45.5 * | 163.5 ± 53.7 ** | 189.8 ± 64.3 *** | 118.1 ± 36.2 † | 161.3 ± 48.1 †† | 194.0 ± 44.9 ††† |
| BROS (×103) | 3.20 ± 3.40 | 4.10 ± 5.95 | 4.05 ± 6.95 | 3.28 ± 3.83 | 3.41 ± 6.69 | 3.34 ± 3.06 |
| SROS (×106) | 7.52 ± 3.75 | 7.46 ± 3.24 | 7.67 ± 3.55 | 6.74 ± 3.28 † | 5.81 ± 2.30 | 5.91 ± 2.91 ††† |
Tukey’s honestly significant difference test of between the three age cohorts. * †, compared 20–44 years with 44–64 years, p < 0.05; ** ††, compared 45–64 years with ≥65 years, p < 0.05; *** †††, compared 20–44 years with ≥65 years, p < 0.05. AA: arachidonic acid, BMI: body mass index, BROS: basal reactive oxygen species, DGLA: dihomo gamma linolenic acid, DHA: docosahexaenoic acid, EPA: eicosapentaenoic acid, SROS: stimulated reactive oxygen species.